Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Show more
Location: 601 Brickell Key Drive, Miami, FL, 33131, United States | Website: https://www.smmttx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
13.44B
52 Wk Range
$15.55 - $36.91
Previous Close
$18.12
Open
$17.76
Volume
5,527,902
Day Range
$17.76 - $18.54
Enterprise Value
13.15B
Cash
297.9M
Avg Qtr Burn
-51.72M
Insider Ownership
84.35%
Institutional Own.
13.55%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC (2L+ EGFRm NSCLC) | BLA Submission | |
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC | BLA Submission | |
Ivonescimab (SMT112) Details 1L Non-small cell lung carcinoma | BLA Submission | |
Ivonescimab Details 1L PD-L1 positive Non-small cell lung carcinoma | Phase 3 Data readout | |
Ivonescimab Details PD-L1 positive NSCLC | Phase 3 Update | |
Ivonescimab (SMT112) +Chemotherapy Details Biliary Tract Cancer | Phase 2 Update | |
Ridinilazole Details Intestinal infection, Bacterial infection | Failed Discontinued |